Neurodegenerative Disease Diagnosis: Which Exam, Imaging and Lab Tests Come First?

She had written the shopping list twice, found both copies in her coat pocket, and laughed it off. Her daughter did not laugh. Six weeks later they were sitting in a neurology waiting room, each holding a different fear: one worried about a scan, the other about being told it was nothing and sent home.

That is the ordinary starting point for most people who end up asking about neurodegenerative disease diagnosis tests. The questions are practical. Will there be a brain scan today? Is there a blood test? Why does the doctor keep asking about sleep, mood and falls when the problem is memory? And underneath all of it, the quiet one: how long until we know?

The honest answer is that the process is a sequence, not a single verdict, and the order of that sequence matters more than any one test. This explainer walks through what comes first, what comes later, and what each step can and cannot tell you.

What actually happens at a first appointment for neurodegenerative disease diagnosis tests

The first visit is mostly talking, and that is deliberate. A neurodegenerative disease is a condition in which nerve cells in the brain or spinal cord gradually lose function and die, so the clinician’s first job is to understand the shape of the change over time: when it started, what was noticed first, whether it has crept forward steadily or arrived in steps, and what else has shifted alongside it.

Expect to be asked about things that may seem unrelated. Changes in sleep, including acting out dreams, can point toward one group of conditions. A loss of smell, constipation, a softer voice or smaller handwriting can point toward another. Falls, fainting, tremor, mood changes, hallucinations and new difficulty with money or medicines all carry diagnostic weight. The Mayo Clinic notes that a family member or close friend is usually asked to describe what they have seen, because the person affected may not notice or remember every change.

A full medication review follows. Several common drug classes, including sedatives, strong antihistamines and some bladder or pain medicines, can slow thinking on their own, and a clinician will want to know everything being taken, including over-the-counter products and supplements, before interpreting any test.

Only then does the physical examination begin. In a single visit the clinician can usually complete the history, the general and neurological examination and a short cognitive screen, then order blood tests and imaging. Hearing and vision are often checked too, because an uncorrected sensory loss can masquerade as confusion.

What you will not usually get on day one is a label. In the clinic, a first visit is designed to build a working picture and to exclude the conditions that look like neurodegeneration but are not, which is where the next steps come in.

Why the neurological exam for dementia comes before any scan

People are sometimes surprised, even a little frustrated, that the scan does not come first. The reason is that a neurological examination, a hands-on assessment of movement, reflexes, sensation, coordination, eye movements, speech and thinking, can localize a problem in a way no image can. An MRI shows structure. The examination shows function.

Here is a concrete example. Two people arrive with slowed thinking. One has a subtle shuffle, reduced arm swing on one side and a faint resting tremor; the other walks normally but struggles to copy a simple drawing and cannot recall three words after a few minutes. Those two examinations send the clinician down quite different paths before a single test has been ordered, and they shape which scan is chosen and how it is read.

The examination also catches things that would otherwise be missed. Brisk reflexes with muscle twitching suggest a motor neuron problem. Difficulty moving the eyes up and down is a clue to a specific parkinsonian condition. A wide, unsteady walk with urinary urgency raises the possibility of a fluid-pressure problem in the brain that can sometimes be treated.

A neurologist, a doctor who specializes in diseases of the brain, spinal cord and nerves, will also be judging alertness, attention and mood throughout the conversation. Depression and delirium, which is a sudden, fluctuating confusion often caused by illness or medicines, both impair thinking and both are reversible, so they need to be identified before anyone talks about degeneration.

The National Institute on Aging describes this combination of history, physical and neurological examination and mental status assessment as the foundation of the workup. Imaging and laboratory tests are layered on top to confirm or challenge the picture the examination has built. Skipping ahead to a scan without that foundation risks finding an incidental change and blaming it for the wrong problem.

How is dementia diagnosed? Cognitive screening tests explained

Dementia is a broad term for a decline in memory, thinking or reasoning severe enough to interfere with daily life, and it is a description rather than a single disease. The World Health Organization estimates that more than 55 million people live with dementia worldwide and that Alzheimer’s disease accounts for roughly 60 to 70 percent of cases, with vascular, Lewy body and frontotemporal dementias making up much of the rest.

Diagnosing it starts with short, structured tests of thinking done at the desk. These typically take 10 to 15 minutes and ask you to remember a short list of words, name the date and place, draw a clock face, name animals or copy a shape. They are sometimes called mental status or cognitive screening tests. The score is useful, but the pattern is more useful: trouble with recall but intact attention points one way, intact recall with poor planning and judgment points another.

Two things are worth knowing. First, these screens are not a diagnosis on their own. Education, language, hearing, anxiety and a bad night’s sleep all move the score. Second, a normal screen does not rule out an early problem, which is why a clinician who still has concerns may refer for formal neuropsychological testing, a longer session with a specialist psychologist that maps strengths and weaknesses across memory, language, attention and visual skills in far more detail.

The NHS and the Mayo Clinic both describe this layered approach: a brief screen in primary care, then fuller testing and imaging through a memory clinic or neurology service if the screen or the story is concerning. A diagnosis of a specific dementia is made by combining the test pattern with the examination, blood results and imaging, and in some cases with specialized biomarker tests described later. No single number on a screening test settles it.

Which lab tests come first, and what are they really looking for

The first round of blood tests is not designed to prove a neurodegenerative disease. It is designed to find something else. This distinction matters, because a good share of people referred for memory or movement changes turn out to have a contributing problem that can be treated.

According to the National Institute on Aging and the Mayo Clinic, a standard initial panel typically includes:

• Thyroid function, because an underactive thyroid slows thinking and movement.
• Vitamin B12 and sometimes folate, since deficiency can cause memory loss, numbness and unsteadiness.
• A full blood count to look for anemia or infection.
• Kidney and liver function, blood sugar and electrolytes such as sodium and calcium, any of which can cloud cognition when abnormal.
• In selected cases, tests for syphilis, HIV or vitamin D, guided by history.

A urine test may be added if infection is possible, especially in older adults, in whom a urinary infection can present as sudden confusion rather than pain.

None of these results will say Alzheimer’s or Parkinson’s on the report. What they do is clear the ground. If the B12 is low, that is corrected and thinking is reassessed before anyone moves on. If everything is normal, the neurodegenerative question becomes more likely, and the clinician moves to imaging with greater confidence.

A second tier of laboratory work exists for specific situations: genetic testing when a strong family history or very early onset suggests an inherited form, autoimmune antibody panels when the picture is rapidly changing or unusual, or heavy-metal and toxin screens when exposure is plausible. These are not routine, and ordering them without a reason can produce confusing results. The sequencing principle is simple: common, treatable and cheap to find comes first; rare and specialized comes later and only when the story earns it.

Brain scan for memory loss: when CT or MRI is ordered and what it shows

Most people referred for a brain scan for memory loss will have an MRI, which is magnetic resonance imaging, a scan that uses magnets and radio waves rather than radiation to produce detailed pictures of brain tissue. A CT scan, computed tomography, uses X-rays and is faster and more widely available, so it is often chosen when someone cannot have an MRI, for example because of certain implanted devices, or when the question is urgent.

What are these scans for? Two jobs, in order of priority. The first is exclusion: a tumor, a slow bleed under the skull, a stroke, a build-up of fluid or a large area of damaged white matter can each cause thinking or movement changes and each needs its own management. The second is support: patterns of shrinkage, called atrophy, in particular regions can back up a clinical suspicion. Shrinkage of the hippocampus, a seahorse-shaped memory structure deep in the temporal lobe, is common in Alzheimer’s disease; shrinkage at the front and sides of the brain is more typical of frontotemporal dementia; scattered small-vessel changes point toward a vascular contribution.

Two cautions are important. Some degree of atrophy and some white-matter spots are common with normal aging, so a radiology report describing them is not, on its own, a diagnosis. And a normal scan does not exclude early neurodegenerative disease, because cell loss can be real before it is visible. The Mayo Clinic is explicit that structural imaging is used primarily to rule out other conditions and to support the overall picture rather than to prove a specific disease.

If the scan and the clinical picture agree, many people need nothing further. If they disagree, or if the type of condition matters for treatment or planning, the next layer of testing comes into play.

When PET scans, DaTscan and spinal fluid tests come into play

These are the tests that look for the disease process itself rather than its consequences, and they are reserved for cases where the answer would change something.

A PET scan, positron emission tomography, uses a small amount of a radioactive tracer that binds to a target in the brain. One type measures glucose use and shows which regions have slowed down. Others bind to amyloid or tau, the two abnormal proteins that accumulate in Alzheimer’s disease. The National Institute on Aging describes amyloid and tau PET as tools used mainly in specialist settings and research, helpful when the diagnosis is uncertain or when eligibility for amyloid-targeting treatment is being assessed.

A DaTscan is a type of SPECT scan, single-photon emission computed tomography, that shows dopamine transporter activity in the deep brain. Dopamine is the chemical messenger lost in Parkinson’s disease, so a reduced signal supports a parkinsonian condition. The NHS notes that a specialist may arrange this scan when there is doubt about whether symptoms are due to Parkinson’s or something that mimics it, such as essential tremor or drug-induced parkinsonism. It cannot distinguish Parkinson’s disease from several related conditions, so it answers a narrow question well and broader questions poorly.

A lumbar puncture, also called a spinal tap, draws a small sample of cerebrospinal fluid, the clear fluid bathing the brain and spinal cord, through a needle placed in the lower back. The fluid can be measured for amyloid and tau in suspected Alzheimer’s, and it also helps exclude infection, inflammation and some rapid-onset conditions. It is done under local anesthetic; headache afterward is the most common side effect.

Which of these is chosen, and whether any is needed, depends on the specific uncertainty the treating team is trying to resolve. For many people, particularly those whose clinical picture is already clear, none of them is required.

Is there an Alzheimer's blood test yet? What the evidence shows

This is the question in nearly every waiting room, so it deserves a precise answer. Blood tests that measure amyloid and tau-related proteins in plasma now exist, and the evidence behind them has advanced rapidly. In carefully selected patients attending specialist clinics, some of these tests agree closely with PET and spinal fluid results. The National Institute on Aging and the Mayo Clinic both describe them as emerging tools that are becoming available in specialist practice.

Here is the honest qualification. Performance in a specialist memory clinic, where most people already have symptoms and a reasonable prior likelihood of Alzheimer’s, is not the same as performance in a general population or in someone without symptoms. A positive result in a person with no cognitive change does not mean dementia is coming on a schedule, and a negative result in a person with clear decline does not mean nothing is wrong, because many neurodegenerative diseases involve neither amyloid nor tau.

These tests also detect Alzheimer’s biology, not Alzheimer’s dementia. A person can carry the biological change for years without a change in daily life. Current guidance therefore positions blood biomarkers as part of a specialist assessment, alongside the history, examination, cognitive testing and imaging already described, rather than as a stand-alone screen that anyone can order to settle the matter.

What the evidence does not yet show is how these results should be used in people without symptoms, how they perform across different ethnic groups and medical conditions, and how often a result would change a care plan. Those studies are under way. For now, the fair statement is that an Alzheimer’s blood test can help a specialist confirm or reduce suspicion in the right patient, and that its place in routine, first-line neurodegenerative disease diagnosis tests is still being defined by evidence rather than settled.

Which test answers which question: a summary of the usual sequence

The sequence below reflects the approach described by the National Institute on Aging, the NHS and the Mayo Clinic. Individual pathways vary with symptoms, age and local services, and the order can be compressed when a presentation is rapid or alarming.

Step	Test	Main question it answers	Usual timing
1	History with an informant and medication review	What has changed, how fast, and could a drug or illness explain it?	First visit
2	Physical and neurological examination	Where in the nervous system is the problem, and what pattern does it fit?	First visit
3	Brief cognitive or movement screen	Is there measurable impairment, and in which domains?	First visit
4	Routine blood and urine tests	Is there a treatable cause such as thyroid, B12, infection or metabolic imbalance?	First or second visit
5	MRI or CT of the brain	Is there a structural cause, and does any shrinkage pattern support the suspicion?	After blood tests, often within weeks
6	Formal neuropsychological testing	What is the detailed profile of strengths and deficits?	When screening is unclear or early
7	PET, DaTscan, spinal fluid or blood biomarkers	Which disease process is present, when that would change management?	Specialist decision, selected cases
8	Nerve conduction, EMG, genetic or autoimmune tests	Reserved for specific presentations such as muscle weakness, early onset or rapid decline	Specialist decision

Read the table from the top down and a pattern emerges: the earlier steps are cheap, quick and aimed at exclusion; the later steps are expensive in time and resources and aimed at confirmation. A test is moved up the list only when the clinical story makes it necessary.

How Parkinson's, ALS and other nerve conditions are tested differently

Memory loss gets most of the public attention, but neurodegenerative disease is a family, not a single member. MedlinePlus lists examples that include Alzheimer’s disease, Parkinson’s disease, amyotrophic lateral sclerosis (ALS), Huntington’s disease, Friedreich’s ataxia, Lewy body dementia and spinal muscular atrophy. Each has its own front door into the diagnostic process.

Parkinson’s disease is a clinical diagnosis. The NHS is clear that no definitive test exists and that a specialist bases the diagnosis on examination findings such as slowness, stiffness and tremor, along with the history. A trial of dopamine-replacing medicine and the response to it can form part of the assessment, with the decision and interpretation resting entirely with the prescribing clinician. Imaging is used to exclude mimics, and a DaTscan is added only when the picture is uncertain.

ALS, a disease of the motor nerves that control voluntary muscles, is approached from the opposite direction. The examination looks for a combination of wasting and twitching alongside brisk reflexes. Nerve conduction studies, which measure how fast electrical signals travel along a nerve, and electromyography (EMG), which records electrical activity in muscle through a fine needle, are central. Blood tests and MRI of the spine are used to exclude compressive and inflammatory causes that can look similar.

Huntington’s disease is the exception where a single test can be decisive: a genetic blood test identifies the responsible gene change. Because the result has implications for relatives, testing is normally offered with formal genetic counseling before and after.

Lewy body dementia and the frontotemporal dementias sit between these poles, diagnosed on the pattern of symptoms with imaging support. The common thread is that the examination decides the route, and the tests follow.

Who is usually tested now, and who is usually asked to wait and be reviewed

Not everyone who worries about their memory needs the full pathway, and not everyone who wants an answer today will get one. Clinicians sort people by how likely a neurodegenerative process is and by how much a test would change what happens next.

People who are usually moved through the pathway promptly include those with a clear, progressive change reported by someone who knows them well; anyone with focal neurological signs on examination, such as weakness on one side or abnormal eye movements; anyone whose change has been rapid, over weeks rather than years; and younger adults with cognitive or movement symptoms, in whom the range of possible causes is wider and includes some that are treatable.

People who are often asked to wait and be reviewed include those with isolated, subjective forgetfulness and a normal screen; those in the middle of a depressive episode, bereavement, poor sleep or a medication change that could explain the symptoms; and those recovering from an acute illness, hospital stay or surgery, during which temporary confusion is common. In these situations the most informative test is time. A repeat assessment after a defined interval, with the confounder addressed, often answers the question better than a scan would.

Watchful review is not dismissal. The NHS Parkinson’s guidance notes that a specialist may need to see someone again before confirming the diagnosis, because early features can be subtle and some mimics declare themselves over months. The same logic applies to early cognitive change, where mild cognitive impairment, a measurable decline that does not yet affect daily independence, may progress, stay stable or even improve.

Whether to test now or review later is a judgment the treating team makes with you, and it is reasonable to ask what would move you from one group to the other.

What the following weeks usually look like, and what a diagnosis leads to

Once the first visit is done, the next stretch is mostly waiting for results and attending for imaging. Blood results typically return within days. Scan scheduling and reporting varies with local services; the NHS and Mayo Clinic both describe a follow-up appointment at which the clinician brings the history, examination, blood work and imaging together and explains what they add up to. If specialist tests are needed, another cycle follows.

It helps to keep a short diary during this period: new symptoms, good and bad days, falls, medication changes, sleep. Clinicians rely on this between visits, and it is easier than reconstructing a month from memory.

What a diagnosis leads to depends on the condition. Current treatments for neurodegenerative diseases fall into a few broad groups, and the National Institute on Aging and Mayo Clinic describe them in similar terms. Symptom-targeting medicines, such as cholinesterase inhibitors in Alzheimer’s or dopamine-replacement therapy in Parkinson’s, aim to support function; they do not reverse the underlying process. Disease-modifying therapies that target amyloid in early Alzheimer’s exist and require biomarker confirmation and monitoring, with eligibility, risks and benefits weighed by the prescribing specialist. Non-drug approaches, including physical therapy, speech and language therapy, occupational therapy, cognitive stimulation and management of hearing, vision, sleep and vascular risk factors, apply across almost every condition. Planning matters too: driving safety, finances, advance care wishes and support for the person who is caring.

None of this is a promise of a particular outcome. Progression rates vary widely between people and between conditions, and the WHO stresses that dementia care is about maintaining function, independence and quality of life for as long as possible. A diagnosis is less an ending than the point at which that planning can begin with accurate information.

What people often get wrong about neurodegenerative disease diagnosis tests

Some misunderstandings come up so often that it is worth naming them directly.

A normal scan means nothing is wrong. Structural MRI can look unremarkable in early disease. The scan excludes other causes and supports the clinical picture; it is not the arbiter. The reverse is also true: mild shrinkage or white-matter spots on a report are common with age and do not equal a diagnosis.

There is one definitive test. For most of these conditions, there is not. Huntington’s disease has a decisive genetic test; Parkinson’s disease, by the NHS’s own account, has none. Diagnosis is a weighing of evidence from several sources.

Forgetting names means Alzheimer’s. Occasional word-finding trouble is common in healthy aging, and it is also a feature of depression, poor sleep, thyroid problems and many medicines. The pattern and progression matter far more than any single lapse.

A blood test can now screen everyone. Blood biomarkers are a specialist tool with good evidence in symptomatic patients at memory clinics. Their use in people without symptoms is not established, and a positive result is not a diagnosis of dementia.

Diagnosis is pointless because nothing can be done. Treatable causes are found in a meaningful minority of people worked up for cognitive change, symptom-supporting treatments exist for several conditions, and safety planning, support services and research access all depend on knowing what is happening.

The doctor is stalling by asking for a review in a few months. Early features can be ambiguous. Observation over time is itself a diagnostic method, and it protects against labeling someone with a progressive disease they do not have.

Scans are harmless, so more is better. Every test carries a chance of an incidental finding that leads to anxiety and further testing without benefit. Ordering in sequence, for a reason, is the safer path.

Questions to ask your care team

Appointments are short and memory under stress is unreliable, so write these down and bring a second person if you can. The aim is to leave each visit knowing what has been found, what is still open and what happens next.

• Based on today’s examination, what do you think is most likely, and what are you trying to rule out?
• Which blood tests are you ordering, and which results would change the plan?
• Will the brain scan be MRI or CT, and what specifically are you looking for on it?
• If the scan is normal, does that end the question or will more tests follow?
• Are any of my current medicines or supplements likely to be affecting my thinking or movement?
• Would formal neuropsychological testing add anything in my case?
• Is a PET scan, DaTscan, spinal fluid test or blood biomarker relevant for me, and what would the result change?
• If you are asking me to come back in a few months, what should I watch for in the meantime, and what would bring the appointment forward?
• Should my family history prompt genetic counseling?
• Who do I contact between visits if something changes quickly?
• Is it safe for me to keep driving, working or managing my own medicines while we wait?
• What written information or support services can I take home today?

Two further questions are worth asking once a diagnosis is reached, because they shape everything after: what does this diagnosis mean for the next year, as far as anyone can honestly say, and what can we start now that will protect function and independence? The answers belong to your treating team, who know your results and your circumstances. Good clinicians welcome the questions; they are how a diagnosis becomes a plan.

When to call your doctor: red-flag signs that should not wait for a scheduled test

Most neurodegenerative conditions change slowly, and most of the testing described here can proceed at a planned pace. Some presentations cannot. Call emergency services immediately if any of the following appear suddenly, because they suggest stroke, bleeding or another acute brain problem rather than a degenerative one:

• Sudden weakness, numbness or drooping on one side of the face or body.
• Sudden slurred speech, inability to speak or inability to understand others.
• Sudden loss of vision, double vision or loss of balance with no clear cause.
• A severe headache unlike any experienced before, especially with vomiting, neck stiffness or drowsiness.
• A first seizure, or a prolonged period of unresponsiveness.

Contact your doctor or the clinic urgently, rather than waiting for the next appointment, if you notice:

• Confusion that has developed over hours or days rather than months, particularly with fever, a new medicine or a recent fall, because delirium and infection are common and treatable.
• A fall with a head injury in someone taking blood thinners, even if they seem fine afterward.
• Rapid decline in thinking or movement over a few weeks.
• New hallucinations, severe agitation or thoughts of self-harm.
• Difficulty swallowing, choking on food or drink, or unexplained weight loss.
• New urinary incontinence together with unsteady walking and confusion.
• Inability to manage essential tasks safely, such as leaving the stove on or wandering at night.

These signs do not mean a particular diagnosis. They mean the timetable should change, and the decision about what to do next belongs to the clinician who sees you. If you are the person caring for someone, trust what you observe and say so plainly; a clear description of what has changed and how fast is the most valuable piece of information you can give.

Frequently asked questions

How is dementia diagnosed, and is there a single test for it?

Dementia is diagnosed by combining a history from the patient and a close contact, a neurological examination, cognitive tests, routine blood work and brain imaging, not by one test. Blood tests exclude treatable causes such as thyroid or B12 problems; MRI or CT excludes structural causes and supports the pattern. Specialized PET, spinal fluid or blood biomarker tests are added only when the type of dementia is uncertain and knowing it would change care.

What does a neurological exam for dementia involve?

It is a hands-on assessment of reflexes, strength, sensation, coordination, walking, eye movements, speech and mental status, usually taking 20 to 30 minutes within the consultation. The clinician is looking for patterns: a shuffle and tremor suggest one direction, difficulty copying drawings or recalling words another. It also screens for depression and delirium, both of which impair thinking and are reversible, so they must be identified before any degenerative diagnosis is considered.

Is a brain scan for memory loss always needed?

Usually yes, at least once, according to Mayo Clinic and NHS guidance, because imaging excludes tumors, bleeds, strokes and fluid build-up that can mimic dementia. MRI is preferred; CT is used when MRI is not possible or speed matters. A scan is not always required immediately in someone with mild, isolated forgetfulness and a normal screen, where review over time may come first. The treating team decides based on the overall picture.

Is there an Alzheimer's blood test I can ask for?

Blood tests measuring amyloid and tau-related proteins exist and are increasingly available through specialist clinics. In symptomatic patients at memory clinics they agree closely with PET and spinal fluid findings. Their use as a screen in people without symptoms is not established, and a positive result shows Alzheimer’s biology rather than dementia. Whether such a test is appropriate for you is a decision for a specialist who has assessed your symptoms.

What are some examples of degenerative neurological diseases?

MedlinePlus lists Alzheimer’s disease, Parkinson’s disease, amyotrophic lateral sclerosis (ALS), Huntington’s disease, Lewy body dementia, Friedreich’s ataxia and spinal muscular atrophy among degenerative nerve diseases. Frontotemporal dementia, multiple system atrophy and progressive supranuclear palsy are others. They share gradual loss of nerve cells but differ in which cells are affected, which is why memory, movement, speech or muscle strength may be the first thing to change.

What are some common brain diseases that can look like neurodegeneration?

Stroke, brain tumors, subdural bleeds after a fall, normal pressure hydrocephalus, infections such as encephalitis, autoimmune inflammation, epilepsy and severe depression can all produce memory, thinking or movement changes that resemble a degenerative disease. Thyroid disease, vitamin B12 deficiency and medication side effects are frequent non-brain causes. Finding these is the main purpose of the first round of blood tests and imaging in the diagnostic sequence.

Can you live a normal life with Alzheimer's?

Many people continue valued activities, relationships and independence for a considerable time after diagnosis, especially when it is made early and support is in place, but the condition is progressive and daily life changes over time. The WHO frames care around maintaining function and quality of life for as long as possible. How quickly things change varies widely between individuals, and no clinician can promise a particular course.

What are the treatment options for neurodegenerative diseases?

Options fall into symptom-supporting medicines, such as cholinesterase inhibitors in Alzheimer’s or dopamine-replacement therapy in Parkinson’s; disease-modifying therapies, such as amyloid-targeting treatments for early Alzheimer’s that require biomarker confirmation and monitoring; and non-drug care including physical, occupational and speech therapy, cognitive stimulation and management of vascular risk, hearing and sleep. Which apply, and whether the benefits outweigh risks, is decided with the prescribing specialist.

How long does it take to get a neurodegenerative disease diagnosis?

There is no fixed interval. Blood results return within days, imaging within weeks in most services, and a follow-up visit brings these together. For Parkinson’s disease the NHS notes a specialist may need to review you again before confirming the diagnosis, and early cognitive changes are often reassessed after an interval. Rapid or alarming presentations are investigated faster. Ask your team what their expected timeline is.

Can I have a lumbar puncture or PET scan to be certain?

These tests are offered when the diagnosis remains uncertain after examination, blood work and MRI, or when confirming the disease process would change treatment eligibility. They are not routine first-line tests, and in someone whose clinical picture is already clear they may add little. A lumbar puncture carries a risk of headache; PET involves a small radiation dose. The specialist weighs these against the value of the information.

References

• National Institute on Aging (NIH): How Is Alzheimer's Disease Diagnosed?
• NHS: Parkinson's disease, Diagnosis
• MedlinePlus: Degenerative Nerve Diseases
• World Health Organization: Dementia fact sheet

This article is for general information only and is not a substitute for professional medical advice. Please consult a qualified doctor about your individual situation.